The success of our innovative drug candidates can benefit millions of cancer patients

After more than 20 years of research and hard work, our company has developed innovative technologies to overcome many of the challenges associated with polysaccharide drug conjugation. We have achieved significant breakthroughs in the fields of polysaccharide functionalization, position-specific taxane functionalization, and the synthesis of polysaccharide-based polymer-drug conjugates.

The first-in-class new drug candidate, CQ-0736, developed from the GlycoTDS™ platform, not only effectively targets the most aggressive RAS-driven pancreatic and lung tumors in vivo without observed toxicity in mice, but also shows strong potential in combination therapy with (pan) RAS inhibitors, CQ-0736 may help overcome the inherent resistance and limitations of these drugs.

Direct head-to-head in vivo studies demonstrated that CQ-0736 significantly outperformed the world-class pan-RAS inhibitor RMC-6236 and the marketed KRAS-targeted drug Krazati (adagrasib). In the H358 CDX model, the in vivo antitumor efficacy of CQ-0736 was 5.56-fold greater than that of RMC-6236 and 9.4-fold greater than that of Krazati (adagrasib). The adagrasib group developed rapid drug resistance, while the RMC-6236 group showed delayed resistance. In contrast, CQ-0736 exhibited reduced resistance and more durable antitumor activity. In the Lu-017 PDX (KRAS G12C) model, the in vivo antitumor efficacy of CQ-0736 was 16.5-fold greater than that of RMC-6236.

The PSMA-targeted drug candidate, CQ-1783, which combines the two active dual mechanisms of action-PSMA receptor targeting and macropinocytosis targeting—demonstrated 15.5-fold greater efficacy and more than a two fold improvement in safety compared to the original drug cabazitaxel.